See more : Ikena Oncology, Inc. (IKNA) Income Statement Analysis – Financial Results
Complete financial analysis of NeuroBo Pharmaceuticals, Inc. (NRBO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NeuroBo Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- IMAC Holdings, Inc. (BACK) Income Statement Analysis – Financial Results
- Axel Polymers Limited (AXELPOLY.BO) Income Statement Analysis – Financial Results
- Drewloong Precision, Inc. (4572.TW) Income Statement Analysis – Financial Results
- Beijing Capital International Airport Company Limited (BJCHY) Income Statement Analysis – Financial Results
- Advanced Powerline Technologies, Inc. (APWL) Income Statement Analysis – Financial Results
NeuroBo Pharmaceuticals, Inc. (NRBO)
About NeuroBo Pharmaceuticals, Inc.
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative, infectious, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which is in Phase 2/3 clinical trials to treat patients with moderate coronavirus disease (COVID-19); NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene, an acute indication for COVID-19. NeuroBo Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 28.00K | 72.00K | 67.00K | 17.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -28.00K | -72.00K | -67.00K | -17.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 9.16M | 2.78M | 6.55M | 21.87M | 17.48M | 14.31M | 22.69M | 8.74M | 3.99M | 52.00K |
| General & Administrative | 6.73M | 8.64M | 8.75M | 7.85M | 2.70M | 8.49M | 60.00K | 5.96M | 3.18M | 214.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.38M | 0.00 | 0.00 | 0.00 |
| SG&A | 6.73M | 8.64M | 8.75M | 7.85M | 2.70M | 8.49M | 10.44M | 5.96M | 3.18M | 214.00K |
| Other Expenses | 0.00 | -83.00K | 0.00 | -1.00K | 12.15M | -178.00K | 10.44M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 15.89M | 11.42M | 15.30M | 29.72M | 20.18M | 22.81M | 33.12M | 14.70M | 7.17M | 266.00K |
| Cost & Expenses | 15.89M | 11.42M | 15.30M | 29.72M | 20.18M | 22.81M | 33.12M | 14.70M | 7.17M | 266.00K |
| Interest Income | 461.00K | 2.19K | 14.00K | 39.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 2.19M | 0.00 | 39.00K | 22.00K | 654.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 7.00K | 28.00K | 72.00K | 67.00K | 17.00K | 6.67M | 60.00K | -17.00K | 2.01M | -1.00K |
| EBITDA | -15.88M | -11.40M | -15.21M | -29.61M | -21.17M | -15.49M | -33.09M | -14.50M | -6.07M | -283.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -15.89M | -19.63M | -15.30M | -29.72M | -20.18M | -22.81M | -33.12M | -14.70M | -8.08M | -266.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 3.42M | 5.66M | 14.00K | 38.00K | -1.14M | -43.00K | -291.00K | 110.00K | -953.00K | -54.00K |
| Income Before Tax | -12.47M | -13.97M | -15.28M | -29.68M | -21.31M | -23.64M | -33.42M | -14.59M | -9.03M | -320.00K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -7.85M | -62.00K | -85.00K | 1.12M | 654.00K | 286.00K | -136.82K | -146.00K | 55.00K |
| Net Income | -12.47M | -6.12M | -15.22M | -29.59M | -22.43M | -23.64M | -33.42M | -14.59M | -9.03M | -320.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.46 | -19.01 | -157.85 | -437.95 | -1.03K | -166.80 | -2.42K | -1.88K | -1.28K | -45.27 |
| EPS Diluted | -2.46 | -19.01 | -157.85 | -437.95 | -1.03K | -166.80 | -2.42K | -1.88K | -1.28K | -45.27 |
| Weighted Avg Shares Out | 5.07M | 321.70K | 96.43K | 67.57K | 21.77K | 141.71K | 13.80K | 7.75K | 7.07K | 7.07K |
| Weighted Avg Shares Out (Dil) | 5.07M | 321.70K | 96.43K | 67.57K | 21.77K | 141.71K | 13.80K | 7.75K | 7.07K | 7.07K |
NeuroBo Pharmaceuticals Announces Exclusive License Agreement with MThera Pharma for NB-01
CAMBRIDGE, Mass. , July 30, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on the transformation of cardiometabolic diseases, today announced the signing of an exclusive license agreement, providing MThera Pharma Co., Ltd.
NeuroBo Pharmaceuticals to Present at the Emerging Growth Conference in July
CAMBRIDGE, Mass. , July 11, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer and Marshall H.
Huge Insider Buying at a Warren Buffett Pick and 5 Other Stocks
24/7 Insights With the second quarter winding up, some insiders are making sizable purchases of stock.
NeuroBo Pharmaceuticals Announces the Closing of up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
$20 million upfront with up to an additional $50 million of aggregate gross proceeds upon the exercise in full of clinical milestone-linked Series Warrants are expected to provide cash runway to complete the Phase 1 Part 3 clinical trial CAMBRIDGE,...
NeuroBo Pharmaceuticals Announces up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
$20 million upfront with up to an additional $50 million of aggregate gross proceeds upon the exercise in full of clinical milestone-linked Series Warrants are expected to provide cash runway to complete the Phase 1 Part 3 clinical trial CAMBRIDGE,...
NeuroBo Pharmaceuticals' DA-1726 Demonstrated Superiority in Weight Loss, Retention of Lean Body Mass, and Lipid-Lowering Effects Compared to Survodutide, in Pre-Clinical Models
DA-1726 Also Exhibited Superior Glucose Lowering Compared to Survodutide Lipid-Lowering Effect of DA-1726 Shown to be Superior Compared to Tirzepatide Data Presented at the ADA 84th Scientific Sessions CAMBRIDGE, Mass. , June 22, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq:...
NeuroBo Pharmaceuticals' DA-1241 in Combination with Semaglutide Improves Liver Fibrosis and Demonstrates Additive Hepatoprotective Effects in Pre-Clinical MASH Models Compared to Either Treatment, Alone
Data Will be Presented in Two Posters at the EASL Congress 2024 CAMBRIDGE, Mass. , May 22, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on the transformation of cardiometabolic diseases, today announced that pre-clinical...
NeuroBo Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
Dosed First Patient in the Single Ascending Dose Part 1 of the Phase 1 Clinical Trial of DA-1726 in Obesity, With Top-Line Data Readout Expected in the Third Quarter of 2024 Anticipate First Patient to be Dosed in the Multiple...
NeuroBo to Present Latest Pre-Clinical Data on Cardiometabolic Assets, DA-1241 and DA-1726, Targeting MASH and Obesity, at Scientific Conferences in June
CAMBRIDGE, Mass. , April 30, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on the transformation of cardiometabolic diseases, today announced the acceptance of poster presentations for its promising cardiometabolic assets, DA-1241 and DA-1726, at the EASL...
NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
Phase 1 Clinical Trial Timelines Significantly Accelerated Top-Line Data Readout from Single Ascending Dose Part 1 Now Expected in the Third Quarter of 2024 First Patient Dosed in the Multiple Ascending Dose Part 2 Expected in the Third Quarter of...
Source: https://incomestatements.info
Category: Stock Reports